Analyzing Nemaura Medical (NASDAQ:NMRD) and PolyPid (NASDAQ:PYPD)

PolyPid (NASDAQ:PYPDGet Free Report) and Nemaura Medical (NASDAQ:NMRDGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Risk & Volatility

PolyPid has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for PolyPid and Nemaura Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolyPid 0 0 1 0 3.00
Nemaura Medical 0 0 1 0 3.00

PolyPid presently has a consensus target price of $14.00, indicating a potential upside of 244.83%. Nemaura Medical has a consensus target price of $2.50, indicating a potential upside of 5,279.81%. Given Nemaura Medical’s higher possible upside, analysts clearly believe Nemaura Medical is more favorable than PolyPid.

Profitability

This table compares PolyPid and Nemaura Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PolyPid N/A -572.69% -110.25%
Nemaura Medical N/A N/A -142.69%

Institutional & Insider Ownership

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 41.6% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares PolyPid and Nemaura Medical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PolyPid N/A N/A -$23.86 million ($12.64) -0.32
Nemaura Medical $80,000.00 23.44 -$14.14 million ($0.39) -0.12

Nemaura Medical has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Nemaura Medical beats PolyPid on 7 of the 10 factors compared between the two stocks.

About PolyPid

(Get Free Report)

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Nemaura Medical

(Get Free Report)

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.